Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/R) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/R) help explain limited loss of bone mineral density over first 12 months
B.F. Murray⁎, M.G. van Vonderen, P.W. Mallon, P. Doran, M.A. van Agtmael, S.A. Danner, P. Lips, P. ReissVolume:
50
Year:
2012
Language:
english
Pages:
1
DOI:
10.1016/j.bone.2012.02.525
File:
PDF, 77 KB
english, 2012